SPRAVATO® (esketamine) CIII

Three people lying on the floor with headphones on, listening to music and resting in a cozy living room with natural light.

You are not alone.

If you’ve tried multiple antidepressants without relief, Sub Rosa Therapy offers a treatment that works differently. SPRAVATO is an FDA-approved medication for treatment-resistant depression, administered on-site in a calm, supportive mental health environment. Our team works closely with you to determine if this treatment fits your needs, and provides integration support throughout the process with the help of your therapist.

What is SPRAVATO?

SPRAVATO® (esketamine) CIII is a nasal spray used in conjunction with an oral antidepressant to treat:

  • Treatment-resistant depression (TRD) in adults

  • Depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior

SPRAVATO® is only available through a certified REMS-treatment center and must be administered under medical supervision.

Spravato for Depression at Sub Rosa in Bozeman

What to Expect at Sub Rosa in Bozeman, Montana

We understand that trying something new can feel overwhelming. At Sub Rosa, SPRAVATO sessions are conducted in a quiet, private room with attentive staff present throughout. We offer:

  • Initial psychiatric evaluation, mental health and medical screening

  • Support with the SPRAVATO® Savings Program and insurance authorization

  • Ongoing therapy with your Sub Rosa therapist and integration support

  • Compassionate medical monitoring from our medical team

Important Safety Information for SPRAVATO®

  • WARNING: SEDATION; DISSOCIATION; ABUSE AND MISUSE; AND SUICIDAL THOUGHTS AND BEHAVIORS
    SPRAVATO® may cause sedation and dissociation. Patients must be monitored for at least two hours after administration. SPRAVATO® is associated with abuse and misuse. SPRAVATO® is only available through a restricted program called the SPRAVATO® REMS. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. SPRAVATO® is not approved for use in pediatric patients.

    • The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated.

    • SPRAVATO® is not approved as an anesthetic agent. Its safety and effectiveness for anesthetic use have not been established.

  • SPRAVATO® is contraindicated in patients with:

    • Aneurysmal vascular disease (e.g., thoracic and abdominal aorta, intracranial, peripheral arterial vessels) or arteriovenous malformation

    • A history of intracerebral hemorrhage

    • Hypersensitivity to esketamine, ketamine, or any of the excipients

  • SPRAVATO® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), due to the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, and abuse/misuse.

    Requirements include:

    • Administered only in certified healthcare settings

    • Patient enrollment in the REMS program

    • Direct observation by a healthcare provider and monitoring for at least 2 hours after each dose

  • To view the full Prescribing Information, including additional warnings, precautions, and clinical data:

    View Full Prescribing Information